Skip to content
OpenCapital
Get started

Taysha Gene Therapies, Inc. TSHA Acquired in-process research and development

Acquired in-process research and development at other companies

Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
$228.9M+1.6%
Biogen logo
BiogenBIIB
$35M—

Other financials

Income statement

See full
Revenue--100%
Operating income-$43.5M-103%
Net income-$42.4M-97.0%
EPS (diluted)-$0.12-50.0%

Balance sheet

See full
Cash & equivalents$276.6M+137%
Total debt$68.6M+11.2%
Total equity$211.9M+285%
Total assets$300.4M+117%

Cash flow

See full
Operating cash flow-$40.9M-85.6%
CapEx$24.0K-93.7%
Free cash flow-$40.9M-82.6%

Valuation

See full
Market cap$1.99B+351%

Profitability

See full
Operating margin-1,774.4%+1,437pp
Net margin-1,738.4%+1,407pp
FCF margin-1,503.6%+621pp

Returns & leverage

See full
Return on equity-97.3%-27.3pp
Debt / equity0.3×-0.8×
Current ratio14×+8.7×

Where this comes from

Reported directly by Taysha Gene Therapies, Inc. in its filing.

Tagged under the XBRL concept us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment.

The official record: Taysha Gene Therapies, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Taysha Gene Therapies, Inc.'s acquired in-process research and development.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Taysha Gene Therapies, Inc.'s acquired in-process research and development?
Taysha Gene Therapies, Inc. (TSHA) reported acquired in-process research and development of $3M in Q1 2026.
How has Taysha Gene Therapies, Inc.'s acquired in-process research and development changed year-over-year?
Taysha Gene Therapies, Inc.'s acquired in-process research and development increased by 693.7% year-over-year, from $378K to $3M.